Enveric Biosciences (ENVB) Net Cash Flow Growth (1y) (2011 - 2026)
Enveric Biosciences (ENVB) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 172.72% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 53.21% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 47.11% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.60% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -100.75% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,045.25% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -104.22% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 149.49% |
| 10 | Enveric Biosciences | 5.66 Mn | -2.64 Mn | - | 335.97% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.02% |
| Dec 31, 2025 | 206.62% |
| Sep 30, 2025 | 324.09% |
| Jun 30, 2025 | 49.52% |
| Mar 31, 2025 | -49.33% |
| Dec 31, 2024 | 56.22% |
| Sep 30, 2024 | 85.61% |
| Jun 30, 2024 | 35.84% |
| Mar 31, 2024 | 178.95% |
| Dec 31, 2023 | 44.15% |
| Sep 30, 2023 | -187.41% |
| Jun 30, 2023 | -20.86% |
| Mar 31, 2023 | -218.39% |
| Dec 31, 2022 | 18.53% |
| Sep 30, 2022 | 283.36% |
| Jun 30, 2022 | -83.69% |
| Mar 31, 2022 | -79.36% |
| Dec 31, 2021 | -415.08% |
| Sep 30, 2021 | 592.50% |
| Jun 30, 2021 | -236.82% |